Literature DB >> 33555495

Iron metabolism is disturbed and anti-copper treatment improves but does not normalize iron metabolism in Wilson's disease.

Grażyna Gromadzka1, Diana Wierzbicka2, Tomasz Litwin2, Adam Przybyłkowski3.   

Abstract

Wilson's disease (WD) is a rare hereditary disorder of copper metabolism. Some data suggest that iron metabolism is disturbed in WD and this may affect the course of the disease. The current study aimed to determine whether anti-copper treatment could affect iron metabolism in WD. One hundred thirty-eight WD patients and 102 controls were examined. Serum ceruloplasmin and copper were measured by colorimetric enzyme assay or atomic adsorption spectroscopy, respectively. Routine and non-routine parameters of iron metabolism were measured by standard laboratory methods or enzyme immunoassay, respectively. WD patients, both newly diagnosed and treated, had less serum copper and ceruloplasmin than controls (90.0, 63.0, 22.0 mg/dL, respectively, p < 0.001); in the treated patients blood copper and ceruloplasmin were lower than in untreated patients (p < 0.001). Untreated patients (n = 39) had a higher median blood iron (126.0 vs 103.5 ug/dL, p < 0.05), ferritin (158.9 vs 47.5 ng/mL, p < 0.001), hepcidin (32, 6 vs 12.1 ng/mL, p < 0.001) and sTfR (0.8 vs. 0.7 ug/mL, p < 0.001) and lower blood transferrin (2.4 vs. 2.7 g/L, p < 0.001), TIBC (303.0 vs 338.0 ug/dL, p < 0.001), hemoglobin (13.1 vs 13.9 g/dL, p < 0.01) and RBC (4.3 vs. 4.6, p < 0.002) than controls. Treated patients (n = 99) had a significantly lower median iron (88.0 vs. 126.0 ug/dL, p < 0.001), ferritin (77.0 vs. 158.9 ng/mL, p < 0.005) and hepcidin (16.7 vs. 32.6 ng/mL, p < 001) and higher transferrin (2.8 vs. 2.4 g/L, p < 0.005), TIBC (336.0 vs 303.0 ug/dL, p < 0.001), RBC (4.8 vs. 4.3 M/L, p < 0.001) and hemoglobin (14.4 vs. 13.1 g/dL, p < 0.001) than untreated; the median iron (p < 0.005) was lower, and ferritin (p < 0.005), RBC (p < 0.005) and hepcidin (p < 0.002) were higher in them than in the control group. Changes in copper metabolism are accompanied by changes in iron metabolism in WD. Anti-copper treatment improves but does not normalize iron metabolism.

Entities:  

Keywords:  Copper; Iron; Wilson disease

Mesh:

Substances:

Year:  2021        PMID: 33555495      PMCID: PMC7940312          DOI: 10.1007/s10534-021-00289-x

Source DB:  PubMed          Journal:  Biometals        ISSN: 0966-0844            Impact factor:   2.949


  26 in total

Review 1.  The physiology of lactoferrin.

Authors:  Jeremy H Brock
Journal:  Biochem Cell Biol       Date:  2002       Impact factor: 3.626

2.  Hepatocyte transplantation in the Long Evans Cinnamon rat model of Wilson's disease.

Authors:  Seon Mee Park; Kim Vo; Michel Lallier; Alexis-Simon Cloutier; Pierre Brochu; Fernando Alvarez; Steven R Martin
Journal:  Cell Transplant       Date:  2006       Impact factor: 4.064

3.  Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study.

Authors:  U Merle; M Schaefer; P Ferenci; W Stremmel
Journal:  Gut       Date:  2006-05-18       Impact factor: 23.059

4.  Influence of IL-1RN intron 2 variable number of tandem repeats (VNTR) polymorphism on the age at onset of neuropsychiatric symptoms in Wilson's disease.

Authors:  Grazyna Gromadzka; Anna Członkowska
Journal:  Int J Neurosci       Date:  2010-10-13       Impact factor: 2.292

5.  Iron metabolism and the role of HFE gene polymorphisms in Wilson disease.

Authors:  Jan Pfeiffenberger; Daniel N Gotthardt; Thomas Herrmann; Jessica Seessle; Uta Merle; Peter Schirmacher; Wolfgang Stremmel; Karl Heinz Weiss
Journal:  Liver Int       Date:  2011-10-17       Impact factor: 5.828

Review 6.  Genetic and environmental modifiers of Wilson disease.

Authors:  Valentina Medici; Karl-Heinz Weiss
Journal:  Handb Clin Neurol       Date:  2017

7.  Difference in iron metabolism may partly explain sex-related variability in the manifestation of Wilson's disease.

Authors:  Grażyna Gromadzka; Diana Wierzbicka; Tomasz Litwin; Adam Przybyłkowski
Journal:  J Trace Elem Med Biol       Date:  2020-08-28       Impact factor: 3.849

8.  Brain metal accumulation in Wilson's disease.

Authors:  T Litwin; G Gromadzka; G M Szpak; K Jabłonka-Salach; E Bulska; A Członkowska
Journal:  J Neurol Sci       Date:  2013-04-15       Impact factor: 3.181

9.  Brain iron accumulation in Wilson disease: a post mortem 7 Tesla MRI - histopathological study.

Authors:  P Dusek; E Bahn; T Litwin; K Jabłonka-Salach; A Łuciuk; T Huelnhagen; V I Madai; M A Dieringer; E Bulska; M Knauth; T Niendorf; J Sobesky; F Paul; S A Schneider; A Czlonkowska; W Brück; C Wegner; J Wuerfel
Journal:  Neuropathol Appl Neurobiol       Date:  2016-10-04       Impact factor: 8.090

Review 10.  Diagnosis and phenotypic classification of Wilson disease.

Authors:  Peter Ferenci; Karel Caca; Georgios Loudianos; Georgina Mieli-Vergani; Stuart Tanner; Irmin Sternlieb; Michael Schilsky; Diane Cox; Frieder Berr
Journal:  Liver Int       Date:  2003-06       Impact factor: 5.828

View more
  2 in total

Review 1.  Cerebral Iron Deposition in Neurodegeneration.

Authors:  Petr Dusek; Tim Hofer; Jan Alexander; Per M Roos; Jan O Aaseth
Journal:  Biomolecules       Date:  2022-05-17

2.  Acute-Onset Visual Impairment in Wilson's Disease: A Case Report and Literature Review.

Authors:  Zi-Wei Zheng; Meng-Hui Xu; Chuan-Bin Sun; Zhi-Ying Wu; Yi Dong
Journal:  Front Neurol       Date:  2022-06-14       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.